Brazil Class III and IV Registration: Dossier Requirements and CBPF

1. Key takeaways

Class III (high-risk) and Class IV (maximum-risk) devices in Brazil go through the registration (registro) pathway. In the required document list, the item that actually blocks approval is not the technical documentation but the CBPF: Article 14(V) of RDC 751/2022, together with its paragraphs 2 and 3, makes publication of the CBPF in the DOU a precondition of approval — an acceptance receipt can be accepted at intake, but no approval is issued before publication. GRZAN’s judgment is that running the CBPF in parallel with the product documentation, rather than queuing it serially, is the single most effective move to compress the overall timeline. And because the CBPF is mandatory only for Class III/IV production units, that boundary determines which items on the list are actually mandatory.

2. Legal basis

• Requirements for the classification, notification and registration of medical devices and for labeling and instructions for use — RDC nº 751/2022, resolution of September 15, 2022: Article 14(III), Article 14(IV), Article 14(V) and its paragraphs 2 and 3
• Requirements for the classification, notification and registration of medical devices and for labeling and instructions for use — RDC nº 751/2022, resolution of September 15, 2022: Article 7, Article 13(II), Article 11, Article 10(8), Article 56, Article 57 and Annex II
• Granting and renewal of the CBPF — RDC nº 687/2022, effective June 1, 2022: Article 3

3. Expert insights

GRZAN reads the logic of the Article 14 list in three layers. The first layer is entity-eligibility documents: imported devices require a letter of authorization (LOA) from the manufacturer, based on Article 13(II) and Article 14(III), plus a certificate of free sale (CFS) or proof of marketing abroad under Article 14(IV). The pitfall in this layer is a broken chain of authorization: when the LOA’s scope, validity period, or signatory authority does not match the product list, this becomes the most common deficiency GRZAN sees at formal review, and the rework cost far exceeds doing it right the first time.

The second layer is production-compliance documents, which is the CBPF. Its mandatory scope is confined by Article 3 of RDC 687/2022 to Class III/IV production units; Classes I/II are not covered, so the mandatory items on the list change with the risk class. Here one field-verified conclusion is key: the CBPF is issued to the manufacturer (the production unit), not to the product, so 1 CBPF held by one factory can support multiple Class III/IV registration applications at the same time. GRZAN’s judgment is that the marginal cost of the CBPF therefore falls as the number of products rises: the broader the product portfolio, the more the certificate should be prioritized.

Article 14(V) with its paragraphs 2 and 3 also provides a buffer: you may file the registration first and complete the CBPF later. At intake, the acceptance receipt can stand in; final approval is conditional on the CBPF being published in the DOU. Chinese-language materials often render this as a requirement to hold a GMP certificate before filing, and GRZAN considers this the easiest error to make and the most expensive one in this article — a project plan built on that understanding wastes an entire cycle for nothing. The correct approach is to time the CBPF to land before approval rather than before submission, running GMP readiness and the registration in parallel so that the two lines converge at the moment of approval. Article 10(8) points the same way at the submission stage (this paragraph was identified through supplementary verification; defer to ANVISA publications).

The third layer is the product’s technical documentation itself, including the Portuguese application form, IFU, and label mock-ups. Many companies put 100% of their effort into this third layer and scramble to assemble the first two at the last minute — the result is that the product file finishes review early while the application stalls on CBPF publication, the classic price of serial queuing.

The technical documentation deserves a separate note: Article 57 requires it to be organized according to the structure of Annex II (Anexo II), tiered by risk class I/II/III/IV, and Chapter 3 of Annex II requires compliance with the regulation in force on essential safety and performance requirements (currently RDC 848/2024). GRZAN’s judgment: using Annex II directly as the table of contents is easier than building a company template, and it avoids the dossier being sent back for restructuring during review.

A frequently confused point: Article 56 provides that under the notification pathway (Classes I/II) the technical dossier is kept by the holder and its physical documents are not submitted to ANVISA at the time of notification, but ANVISA may access them at any time (this sentence was identified through supplementary verification; defer to ANVISA publications). That is a different regime from the Class III/IV registration, which must submit technical documentation per Article 57 and Annex II; the two must not be applied interchangeably.

GRZAN also flags a timing interaction: adding or changing a manufacturing unit is likewise conditional on CBPF publication (Article 24), and post-approval changes that require approval take effect only upon DOU publication (Article 21). Any adjustment on the manufacturing side therefore falls back onto the precondition in Article 14(V): once a production unit expands or moves, the product side has to be resequenced.

4. Practical recommendations

First, zero out the checklist. The GRZAN regulatory team recommends building a table item by item against Article 14, tagging the LOA, CFS, CBPF or acceptance receipt, and technical documentation groups with a responsible party and an acquisition timeline for each.

Second, start the CBPF and the product documentation in parallel. For foreign manufacturers, BGMP conformity under RDC 665/2022 covers the whole chain — design, purchasing, production, packaging, labeling, storage and transport, installation, and technical assistance — and the audit-readiness period is long, so the earlier it starts, the more control you keep.

Third, process the CFS and the LOA together. The two documents come from different issuers, and Chinese companies often hit a gap where the CFS is ready but the LOA is unsigned. GRZAN recommends managing both on the same timeline and keeping their product lists consistent.

Fourth, talk validity only after approval. The registration is valid for 10 years, counted from the DOU publication date; renewal planning should be scheduled separately after the certificate is granted and should not consume submission-phase resources.

Fifth, freeze the manufacturing side and the product side together. Between submission and approval, avoid adding or changing production units; otherwise the CBPF-publication precondition is retriggered and completed review progress may have to be resequenced.

5. Verification checklist

• □ The risk class is confirmed as Class III or IV, and the pathway is registration (registro)
• □ The LOA has been issued, with scope, validity, and signatory authority matching the product list
• □ The CFS or proof of marketing abroad has been obtained and is within its validity period
• □ The CBPF has been initiated; where unpublished, an acceptance receipt has been obtained and confirmed as an acceptable interim
• □ The CBPF is scheduled to land before approval rather than before submission, running in parallel with the registration filing
• □ It has been confirmed that the same manufacturer’s CBPF covers all Class III/IV products in this filing
• □ The application form, IFU, and label mock-ups exist in Portuguese and match the product list
• □ Technical documentation is organized per Article 57 and Annex II, tiered by risk class
• □ No production unit has been added or changed between submission and approval

Regulatory information verified as of October 29, 2026

GRZAN Regulatory Affairs Team

GRZAN helps manufacturers navigate ANVISA registration pathways and classification strategy for the Brazilian market, from Class III/IV dossier assembly under RDC 751/2022 to CBPF planning under RDC 687/2022 and parallel-tracking GMP readiness with product filings. If you need a submission plan in which the CBPF and the technical file converge at approval instead of queuing, talk to the GRZAN regulatory team at info@grzanglobal.com.